FDA Approves TREGZI to Reduce Chronic GVHD After Matched Donor Transplants

If you or a loved one is facing an allogeneic (donor) stem cell transplant, one long-term worry is chronic graft-versus-host disease (cGVHD). cGVHD can affect different body systems and can require ongoing treatment and follow-up.

On June 30, 2026, the FDA approved TREGZI, an allogeneic regulatory T-cell–based cell therapy. The goal is to reduce the risk of cGVHD after certain matched-donor transplants. Below is what the pivotal evidence showed, how the key endpoint was defined, and the questions patients can bring to their transplant team.

Quick context: What is chronic GVHD?

After an allo-HSCT, donor immune cells can react against the transplant recipient’s tissues. cGVHD is a chronic (long-lasting) complication that can develop in some patients and may involve issues such as skin or mouth symptoms, eye dryness, liver inflammation, and lung involvement. The exact mix of symptoms varies from person to person, and long-term follow-up is often needed.

What the FDA approved: TREGZI for adults after matched-donor HSCT

FDA’s approval covers adult patients with certain blood cancers who receive an allogeneic hematopoietic stem cell transplant from a closely matched donor (described by FDA materials as an 8/8 HLA-matched related or unrelated donor) after chemotherapy conditioning.

In the FDA announcement, TREGZI is described as a donor-derived, regulatory T-cell–based product that includes multiple components (including HSPCs and both regulatory and conventional T-cell components) prepared from a closely matched donor.

The pivotal evidence: PRECISION-T (randomized phase 3)

FDA based the approval on results from the PRECISION-T trial, reported in a peer-reviewed publication (randomized phase 3) and listed in ClinicalTrials.gov.

Participants: 187 adults with acute leukemia or myelodysplastic syndrome undergoing myeloablative conditioning followed by allo-HSCT with an HLA-matched donor.
Comparison: TREGZI plus standard GVHD prophylaxis approach versus standard-of-care allogeneic transplant using tacrolimus and methotrexate.
Why randomization matters: Randomization helps balance factors between groups, but the trial still reflects a specific transplant setting and eligibility criteria.

How the main endpoint was defined (what “chronic GVHD-free survival” means)

FDA describes the primary endpoint as a time-to-event measure from transplant to whichever happens first:

Death from any cause, or
The first onset of moderate or severe cGVHD

…within a defined follow-up window (up to two years after day 0). This matters because it treats death and moderate-to-severe cGVHD as outcomes that “stop the clock,” so interpretation should follow the trial’s endpoint rules.

What the results mean in everyday terms

At 1 year, FDA reports:

Chronic GVHD-free survival: 78% with TREGZI vs 38.4% with standard care.
Serious cGVHD (accounting for death as a competing risk): 12.6% with TREGZI vs 44% with standard care.

Put simply: in the trial, a much larger share of patients in the TREGZI group were not yet reaching the study’s “moderate-to-severe cGVHD or death” threshold by one year, and the probability of serious cGVHD was lower when the analysis properly considered that some patients may not live long enough to develop cGVHD.

Potential day-to-day impact—and the limits of what we know

The endpoint focuses on the first year and the trial’s defined window. That means the results are most directly telling us about moderate-to-severe cGVHD avoidance early after transplant—an outcome that can strongly affect long-term health, follow-up intensity, and quality of life.

FDA’s announcement also notes side effects were generally consistent with what is expected around transplant, and infections were among the most commonly reported side-effect types in the trial context. Even with careful monitoring in transplant care, patients are still typically advised to seek prompt evaluation for concerning symptoms.

Who should ask about TREGZI? Questions for the transplant team

If you’re considering an allo-HSCT, you can ask your transplant team questions that map directly to FDA’s evidence and endpoint:

Indication fit: “Does my diagnosis, age, and planned transplant setting match the FDA-approved population?”
Endpoint tracking: “How does your center monitor for moderate-to-severe cGVHD in the time frame used in the PRECISION-T endpoint?”
Monitoring plan: “What will follow-up involve in the first year, and what signs should trigger urgent calls?”
Risks relevant to me: “What side effects were most common in the trial, and how does that translate to my infection-risk and overall risk profile?”

What remains uncertain

Longer-term outcomes: The pivotal endpoint is assessed within a defined window; patients may want to understand what additional follow-up is expected beyond that period.
Real-world effectiveness: Trial participants may differ from routine practice in ways that can affect how benefits and risks play out.
How transplant variations matter: Results are specific to the studied transplant context and eligible patient group; other scenarios should be reviewed case-by-case.

Reasonable next step for readers

If transplant is being planned, bring the question of cGVHD risk reduction into the conversation early. A practical step is to ask whether TREGZI is appropriate in your specific FDA-approved transplant setting—and to confirm exactly how your team will monitor for cGVHD and manage infection-related risks.

When to seek urgent care: After transplant, contact your transplant team promptly for urgent or rapidly worsening symptoms (for example, fever or trouble breathing). If symptoms are severe or accelerating, follow your transplant program’s emergency instructions or seek emergency care.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.